Bridged Bicyclic Cores Containing a 1,1-Diarylethylene Motif Are High-Affinity Subtype-Selective Ligands for the Estrogen Receptor-Reference-Cited by-同舟云学术

Bridged Bicyclic Cores Containing a 1,1-Diarylethylene Motif Are High-Affinity Subtype-Selective Ligands for the Estrogen Receptor

Published:2003-04-01 Issue:9 Volume:46 Page:1589-1602
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Muthyala Rajeev S.¹,Sheng Shubin¹,Carlson Kathryn E.¹,Katzenellenbogen Benita S.¹,Katzenellenbogen John. A.¹

Affiliation:

1. Department of Chemistry, Department of Molecular and Integrative Physiology, and Department of Cell and Structural Biology, University of Illinois, Urbana, Illinois 61801

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm0204800

Reference49 articles.

1. Estrogen receptor transcription and transactivation Estrogen receptor alpha and estrogen receptor beta: regulation by selective estrogen receptor modulators and importance in breast cancer

2. Artificial Estrogens

3. Synthetic Estrogens and the Relation Between their Structure and their Activity.

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantum-Chemical Study of Formation of Alkyl- and Alkenyladamantanes by Ionic Alkylation with Olefins;Kinetics and Catalysis;2024-04

2. Quantum Chemical Study of the Production of 1-Vinyladamantane As a Result of Ionic Alkylation of Adamantane with Ethylene;Russian Journal of Physical Chemistry A;2024-02

3. Molecular cloning of estrogen receptor and its function on vitellogenesis in pompano (Trachinotus ovatus);General and Comparative Endocrinology;2024-01

4. Allosteric targeting resolves limitations of earlier LFA-1 directed modalities;Biochemical Pharmacology;2023-05

5. Different routes for the construction of biologically active diversely functionalized bicyclo[3.3.1]nonanes: an exploration of new perspectives for anticancer chemotherapeutics;RSC Advances;2023